Normal view MARC view ISBD view

Fertility after Curative Therapy for Sickle Cell Disease: A Comprehensive Review to Guide Care. [Review]

MedStar author(s):

, MedStar Georgetown University Hospital/MedStar Washington Hospital Center

Citation: Journal of Clinical Medicine. 11(9), 2022 Apr 21.PMID: 35566443Department: MedStar Georgetown University Hospital/MedStar Washington Hospital Center | Urology Residency-AdvancedForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewYear: 2022 ISSN:

2077-0383

Name of journal: Journal of clinical medicineAbstract: Curative therapy for sickle cell disease (SCD) currently requires gonadotoxic conditioning that can impair future fertility. Fertility outcomes after curative therapy are likely affected by pre-transplant ovarian reserve or semen analysis parameters that may already be abnormal from SCD-related damage or hydroxyurea treatment. Outcomes are also likely affected by the conditioning regimen. Conditioning with myeloablative busulfan and cyclophosphamide causes serious gonadotoxicity particularly among post-pubertal females. Reduced-intensity and non-myeloablative conditioning may be acutely less gonadotoxic, but more short and long-term fertility outcome data after these approaches is needed. Fertility preservation including oocyte/embryo, ovarian tissue, sperm, and experimental testicular tissue cryopreservation should be offered to patients with SCD pursing curative therapy. Regardless of HSCT outcome, longitudinal post-HSCT fertility care is required.All authors: Davis MF, Hsieh MH, Hsieh MM, Maher JY, Nickel RS, Pecker LHFiscal year: FY2022 Digital Object Identifier:

https://dx.doi.org/10.3390/jcm11092318

Date added to catalog: 2022-07-06

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	35566443	Available		35566443

Curative therapy for sickle cell disease (SCD) currently requires gonadotoxic conditioning that can impair future fertility. Fertility outcomes after curative therapy are likely affected by pre-transplant ovarian reserve or semen analysis parameters that may already be abnormal from SCD-related damage or hydroxyurea treatment. Outcomes are also likely affected by the conditioning regimen. Conditioning with myeloablative busulfan and cyclophosphamide causes serious gonadotoxicity particularly among post-pubertal females. Reduced-intensity and non-myeloablative conditioning may be acutely less gonadotoxic, but more short and long-term fertility outcome data after these approaches is needed. Fertility preservation including oocyte/embryo, ovarian tissue, sperm, and experimental testicular tissue cryopreservation should be offered to patients with SCD pursing curative therapy. Regardless of HSCT outcome, longitudinal post-HSCT fertility care is required.

English